One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Albireo Pharma logo
Albireo Pharma ALBO
report update icon

Quarterly report 2022-Q3
added 05-23-2026

Albireo Pharma Balance Sheet 2021-2004 | ALBO

Brief overview of Albireo Pharma's financial position

The comparison uses five available annual reports from the 2017–2021 interval.

Total assets increased by +312.5%, from $73.2 million to $302.1 million. A CAGR near 42.5% points to substantial expansion.

Funding shifted toward liabilities: they gained +1,486.3%, compared with +312.5% for assets.

Equity accounts for 58.1% of assets. Against the initial 89.1%, the capital position looks resilient.

Cash exceeds interest-bearing debt, producing net debt of -$235.9 million. The balance sheet therefore carries a net cash position.

Cash represents 82.1% of assets versus 72.7% initially, showing how the immediate liquidity reserve changed.

The balance sheet includes a negative accumulated result of -$300.9 million. It should be assessed alongside historical profits and capital distributions.

What the balance sheet shows

Albireo Pharma's financial position is more positive than negative: the funding mix is workable, although the cushion is not unlimited.

Annual Balance Sheet Albireo Pharma

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004

Net Debt

-236 M -247 M -127 M -164 M -53.2 M -28.7 M 2.26 M -24.6 M -39.8 M -39 M -38.7 M - - - - - - -

Long Term Debt

10.8 M 3.56 M 4.19 M - - - 4.87 M - - - - - - - - - - -

Long Term Debt Current

1.4 M 640 K 561 K - - 3.08 M 2.51 M - - - - - - - - - - -

Total Non Current Liabilities

- 79.1 M 53 M 50 M 42 K 359 K 59 K 1.01 M 6.15 M 7.34 M 1.14 M - - - - - - -

Total Current Liabilities

45.3 M 25.3 M 18.9 M 12.8 M 7.93 M 12.7 M 8.28 M 1.62 M 2.44 M 2.78 M 3.29 M 4.39 M - - - - - -

Total Liabilities

126 M 104 M 71.9 M 62.8 M 7.97 M 12.7 M 15.2 M 2.63 M 8.59 M 10.1 M 4.43 M 8.56 M - - - - - -

Retained Earnings

-301 M -267 M -159 M -96.5 M -50.4 M -25.9 M -9.6 M -230 M -215 M -196 M -175 M - - - - - - -

Total Assets

302 M 286 M 165 M 185 M 73.2 M 49.7 M 6.97 M 25.4 M 41.2 M 41.1 M 41.5 M 32.6 M - - - - - -

Cash and Cash Equivalents

248 M 251 M 132 M 164 M 53.2 M 29.9 M 5.12 M 8.18 M 39.8 M 39 M 38.7 M 22.9 M 54.6 M 64.7 M - - - -

Book Value

176 M 181 M 93.2 M 123 M 65.3 M 37 M -8.22 M 22.8 M 32.6 M 31 M 37.1 M 24.1 M - - - - - -

Total Shareholders Equity

176 M 181 M 93.2 M 123 M 65.3 M 37 M -8.74 M -2.33 M 32.6 M 31 M 37.1 M 24.1 M 50.5 M 88.5 M 77.2 M 16.3 M 654 K 580 K

All numbers in USD currency

Quarterly Balance Sheet Albireo Pharma

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

- - - - 10.8 M - - - 3.56 M - - - 4.19 M 4.33 M 200 K 213 K - - - - - - - - - - - - 4.87 M - - - - - - - - - - - - - - - - - - -

Total Liabilities

- 221 M 115 M 113 M 126 M 115 M 106 M 102 M 104 M 99.3 M 94.9 M 68.7 M 71.9 M 69.8 M 64.3 M 61.6 M 62.8 M 57.6 M 54.7 M 52.7 M 7.97 M 7.97 M 7.42 M 9.1 M 12.7 M 3.4 M 3.18 M 1.46 M 15.2 M 2.7 M 2.4 M 2.16 M 2.16 M 4.38 M 5.82 M 6.57 M 6.57 M 12.3 M 7.31 M 9.39 M 9.39 M 9.95 M 3.71 M 4.64 M 4.64 M 13.3 M 4.43 M 4.43 M

Retained Earnings

- -421 M -383 M -343 M -301 M -290 M -347 M -311 M -267 M -242 M -211 M -191 M -159 M -152 M -130 M -113 M -96.5 M -80.6 M -66.6 M -52 M -50.4 M -45.3 M -38.8 M -32.6 M -25.9 M -260 M -257 M -252 M -9.6 M -245 M -239 M -252 M - -230 M -230 M - - - - - - - - - - - - -

Total Assets

- 321 M 229 M 261 M 302 M 296 M 219 M 250 M 286 M 311 M 184 M 182 M 165 M 171 M 182 M 173 M 185 M 194 M 204 M 213 M 73.2 M 77.1 M 82.7 M 40.3 M 49.7 M 31.4 M 34.2 M 37.9 M 6.97 M 45.1 M 18.8 M 21 M 21 M 25.7 M 30.3 M 37 M 37 M 44.4 M 30.3 M 37.3 M 37.3 M 46.9 M 34 M 38.1 M 38.1 M 45.1 M 41.5 M 41.5 M

Cash and Cash Equivalents

- 222 M 181 M 217 M 248 M 263 M 186 M 217 M 251 M 279 M 152 M 151 M 132 M 143 M 158 M 150 M 164 M 174 M 183 M 193 M 53.2 M 57.1 M 62.6 M 20.1 M 29.9 M 31 M 33.4 M 36.9 M 5.12 M 44.4 M 17.8 M 19.7 M 8.18 M 24.5 M 28.7 M 35.2 M 35.2 M 42.4 M 27.9 M 34.3 M 34.3 M 43.7 M 29.8 M 35.1 M 35.1 M 42 M 38.7 M 35.1 M

Book Value

- 100 M 114 M 148 M 176 M 182 M 114 M 148 M 181 M 212 M 89.1 M 113 M 93.2 M 102 M 118 M 111 M 123 M 137 M 149 M 160 M 65.3 M 69.1 M 75.3 M 31.2 M 37 M 28 M 31 M 36.5 M -8.22 M 42.4 M 16.4 M 18.9 M 18.9 M 21.4 M 24.5 M 30.4 M 30.4 M 32.1 M 23 M 27.9 M 27.9 M 37 M 30.3 M 33.4 M 33.4 M 31.9 M 37.1 M 37.1 M

Total Shareholders Equity

- 100 M 114 M 148 M 176 M 182 M 114 M 148 M 181 M 212 M 89.1 M 113 M 93.2 M 102 M 118 M 111 M 123 M 137 M 149 M 160 M 65.3 M 69.1 M 75.3 M 31.2 M 37 M 28 M 31 M 36.5 M -8.74 M 42.4 M 16.4 M 18.9 M -2.33 M 21.4 M 24.5 M 30.4 M 30.4 M 32.1 M 23 M 27.9 M 31 M 37 M 30.3 M 33.4 M 33.4 M 31.9 M 37.1 M 33.4 M

All numbers in USD currency

Balance Sheet is a fundamental financial report of Albireo Pharma, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Biotechnology

Issuer Price % 24h Market Cap Country
Taro Pharmaceutical Industries Ltd. Taro Pharmaceutical Industries Ltd.
TARO
- - $ 1.62 B israelIsrael
Omeros Corporation Omeros Corporation
OMER
$ 13.23 -5.71 % $ 840 M usaUSA
BioLineRx Ltd. BioLineRx Ltd.
BLRX
$ 0.94 -10.44 % $ 2.32 B israelIsrael
PhaseBio Pharmaceuticals PhaseBio Pharmaceuticals
PHAS
- 7.4 % $ 6.29 M usaUSA
Forma Therapeutics Holdings Forma Therapeutics Holdings
FMTX
- - $ 958 M usaUSA
Blueprint Medicines Corporation Blueprint Medicines Corporation
BPMC
- - $ 8.14 B usaUSA
Horizon Therapeutics Public Limited Company Horizon Therapeutics Public Limited Company
HZNP
- - $ 26.6 B irlandaIrlanda
Provention Bio Provention Bio
PRVB
- - $ 2.37 B usaUSA
Reata Pharmaceuticals Reata Pharmaceuticals
RETA
- - $ 6.29 B usaUSA
PainReform Ltd. PainReform Ltd.
PRFX
$ 0.47 -24.53 % $ 305 K israelIsrael
iTeos Therapeutics iTeos Therapeutics
ITOS
- - $ 411 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 1.44 -2.03 % $ 2.37 M israelIsrael
PolarityTE PolarityTE
PTE
- -0.82 % $ 1.78 M usaUSA
Kronos Bio Kronos Bio
KRON
- 1.49 % $ 50.8 M usaUSA
Cullinan Management Cullinan Management
CGEM
$ 8.9 -1.93 % $ 536 M usaUSA
CRISPR Therapeutics AG CRISPR Therapeutics AG
CRSP
$ 39.15 0.57 % $ 3.52 B schweizSchweiz
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Stoke Therapeutics Stoke Therapeutics
STOK
$ 26.77 -0.59 % $ 1.59 B usaUSA
Trevena Trevena
TRVN
- -46.58 % $ 31.8 M usaUSA
Calithera Biosciences Calithera Biosciences
CALA
- -10.95 % $ 876 K usaUSA
Molecular Templates Molecular Templates
MTEM
- -23.43 % $ 495 K usaUSA
Oncorus Oncorus
ONCR
- -8.54 % $ 3.19 M usaUSA
BioXcel Therapeutics BioXcel Therapeutics
BTAI
$ 0.07 9.81 % $ 855 K usaUSA
Novan Novan
NOVN
- -24.84 % $ 2.64 M usaUSA
CohBar CohBar
CWBR
- -15.44 % $ 2.2 M usaUSA
NeuBase Therapeutics NeuBase Therapeutics
NBSE
- -1.56 % $ 12.3 M usaUSA
Epizyme Epizyme
EPZM
- - $ 249 M usaUSA
Arena Pharmaceuticals Arena Pharmaceuticals
ARNA
- -6.81 % $ 3.04 B usaUSA
Scopus BioPharma Scopus BioPharma
SCPS
- -48.37 % $ 3.71 M usaUSA
Nabriva Therapeutics plc Nabriva Therapeutics plc
NBRV
- - $ 4.55 M irlandaIrlanda
Annovis Bio Annovis Bio
ANVS
$ 0.71 -3.81 % $ 14.6 M usaUSA
scPharmaceuticals scPharmaceuticals
SCPH
- - $ 218 M usaUSA
Entasis Therapeutics Holdings Entasis Therapeutics Holdings
ETTX
- - $ 105 M usaUSA
Athersys Athersys
ATHX
- 3.77 % $ 22.4 M usaUSA
Global Blood Therapeutics Global Blood Therapeutics
GBT
- - $ 4.62 B usaUSA
Inozyme Pharma Inozyme Pharma
INZY
- - $ 207 M usaUSA
NanoString Technologies NanoString Technologies
NSTG
- -37.43 % $ 5.1 M usaUSA
Humanigen Humanigen
HGEN
- -81.12 % $ 4.28 M usaUSA
CNS Pharmaceuticals CNS Pharmaceuticals
CNSP
$ 3.56 -9.07 % $ 1.58 M usaUSA
Sorrento Therapeutics Sorrento Therapeutics
SRNE
- -29.58 % $ 126 M usaUSA
Surface Oncology Surface Oncology
SURF
- - $ 59.7 M usaUSA
Sierra Oncology Sierra Oncology
SRRA
- -0.05 % $ 1.34 B canadaCanada
Vaccinex Vaccinex
VCNX
- -61.37 % $ 654 K usaUSA
Nymox Pharmaceutical Corporation Nymox Pharmaceutical Corporation
NYMX
- -19.68 % $ 18.4 M canadaCanada
Jounce Therapeutics Jounce Therapeutics
JNCE
- - $ 98.4 M usaUSA
Cocrystal Pharma Cocrystal Pharma
COCP
$ 0.93 -4.11 % $ 10.5 M usaUSA
Fortress Biotech Fortress Biotech
FBIO
$ 1.89 6.78 % $ 52.7 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Longeveron Longeveron
LGVN
$ 1.65 -9.34 % $ 29 B usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA